BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND MYD88, Q99836, MYD88D, 4615
591 results:

  • 1. [New classifications of malignant lymphomas - What changes are relevant for practice?].
    Hartmann S; Rudelius M
    Dtsch Med Wochenschr; 2024 May; 149(11):613-620. PubMed ID: 38749437
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [Isolated primary vitreoretinal lymphoma (case report)].
    Stoyukhina AS; Korobov EN; Smolin SA
    Vestn Oftalmol; 2024; 140(2. Vyp. 2):94-101. PubMed ID: 38739137
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Genomic landscape and distinct molecular subtypes of primary testicular lymphoma.
    Zhang W; Yang P; Yang Y; Liu S; Xu Y; Wu C; Wang J; Liu C; Liu H; Li S; Huang W; Jing H
    J Transl Med; 2024 May; 22(1):414. PubMed ID: 38693538
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Deciphering the Prognostic Significance of myd88 and CD79B Mutations in Diffuse Large B-Cell lymphoma: Insights into Treatment Outcomes.
    Xie Z; Qin Y; Chen X; Yang S; Yang J; Gui L; Liu P; He X; Zhou S; Zhang C; Tang L; Shi Y
    Target Oncol; 2024 May; 19(3):383-400. PubMed ID: 38643457
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. [Ligusticum cycloprolactam inhibits IL-1β-induced apoptosis and inflammation of rat chondrocytes via HMGB1/TLR4/NF-κB signaling pathway].
    Qi X; Chen X; An WB; Xu ZM; Wang DX; Luo PF; Chen YX; Ma JJ; Hu ZY; Qi W; Liu JJ; Liu JX
    Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(4):1007-1016. PubMed ID: 38621908
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics.
    Cao B; Sun C; Bi R; Liu Z; Jia Y; Cui W; Sun M; Yu B; Li X; Zhou X
    BMC Med Genomics; 2024 Apr; 17(1):84. PubMed ID: 38609996
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR.
    Zhong Y; Tan GW; Bult J; Veltmaat N; Plattel W; Kluiver J; Enting R; Diepstra A; van den Berg A; Nijland M
    BMC Cancer; 2024 Apr; 24(1):407. PubMed ID: 38566053
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial.
    Park C; Lee HS; Kang KW; Lee WS; Do YR; Kwak JY; Shin HJ; Kim SY; Yi JH; Lim SN; Lee JO; Yang DH; Jang H; Choi B; Lim J; Sun CH; Byun JM; Yoon SS; Koh Y
    Nat Commun; 2024 Mar; 15(1):2776. PubMed ID: 38555311
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The Genetic Profile of Large B-Cell lymphomas Presenting in the Ocular Adnexa.
    Vest SD; Eriksen PRG; de Groot FA; de Groen RAL; Kleij AHR; Kirkegaard MK; Kamper P; Rasmussen PK; von Buchwald C; de Nully Brown P; Kiilgaard JF; Vermaat JSP; Heegaard S
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542066
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
    Tawfiq RK; Abeykoon JP; Kapoor P
    Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. [miR-515-5p targeting Toll-like receptor 4 regulates myeloid differentiation primary response gene 88/nuclear factor-kappa B pathway to inhibit apoptosis and inflammatory response of osteoarthritis chondrocytes].
    Cai D; Yang Z; Zhong C; Zhang J; Hong S
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2024 Mar; 38(3):315-323. PubMed ID: 38500425
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. How to manage waldenström's macroglobulinemia in 2024.
    Grunenberg A; Buske C
    Cancer Treat Rev; 2024 Apr; 125():102715. PubMed ID: 38471356
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Mutational, immune microenvironment, and clinicopathological profiles of diffuse large B-cell lymphoma and follicular lymphoma with BCL6 rearrangement.
    Carreras J; Ikoma H; Kikuti YY; Miyaoka M; Hiraiwa S; Tomita S; Kondo Y; Ito A; Nagase S; Miura H; Kawada H; Roncador G; Campo E; Hamoudi R; Nakamura N
    Virchows Arch; 2024 Apr; 484(4):657-676. PubMed ID: 38462571
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. A single-centre, real-world study of BTK inhibitors for the initial treatment of myd88
    Deng T; Zhang S; Xiao M; Gu J; Huang L; Zhou X
    Cancer Med; 2024 Feb; 13(4):e7005. PubMed ID: 38457222
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. A Rare Case of Non-IgM Lymphoplasmacytic lymphoma with Unusual Lack of Immunoglobulin Light Chain Production.
    Yin J; Bains A; Alsammak M; Fu JJ
    Am J Case Rep; 2024 Mar; 25():e940963. PubMed ID: 38437184
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
    Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
    Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Nomogram for predicting survival of patients with diffuse large B-cell lymphoma.
    Fujii K; Inagaki A; Masaki A; Sugiura M; Suzuki T; Ishida T; Kusumoto S; Iida S; Inagaki H
    Ann Hematol; 2024 Jun; 103(6):2041-2050. PubMed ID: 38411628
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice.
    Østergaard S; Schejbel L; Breinholt MF; Pedersen MØ; Hammer T; Munksgaard L; Nørgaard P; Høgdall E; Gjerdrum LMR; Nielsen TH
    Leuk Lymphoma; 2024 Jun; 65(6):758-767. PubMed ID: 38340359
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. The impact of myd88 and PIM1 in mature large B-cell non-Hodgkin lymphomas: Defining element of their evolution and prognosis.
    Cristian M; Așchie M; Mitroi AF; Deacu M; Boșoteanu M; Bălțătescu GI; Stoica AG; Nicolau AA; Enciu M; Crețu AM; Caloian AD; Orășanu CI; Poinăreanu I
    Medicine (Baltimore); 2024 Feb; 103(6):e36269. PubMed ID: 38335426
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features.
    Eriksen PRG; de Groot F; Clasen-Linde E; de Nully Brown P; de Groen R; Melchior LC; Maier AD; Minderman M; Vermaat JSP; von Buchwald C; Pals ST; Heegaard S
    Blood Adv; 2024 Apr; 8(8):1946-1957. PubMed ID: 38324724
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 30.